Zealand grants Boehringer Ingelheim exclusive, worldwide rights to dual agonists of glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R; GLP1R)

Zealand Pharma A/S

Denmark / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Boehringer Ingelheim GmbH

Germany / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced